Methods and compositions for inhibition of Treg cells
The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effectore T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen.
1 . A method of suppressing immune tolerance to cancer antigens in a patient comprising:
suppressing the expression of FoxP3 in a patient by administering a therapeutic composition comprising allogeneic activated effector/memory Th1 cells to the patient and chaperone rich cell lysate of the cancer antigens, wherein the Th1 cells are activated by cross-linking of the CD3 and CD28 surface molecules; and
monitoring the FoxP3 expression to ensure the patient maintains suppression of immune tolerance wherein reduction of the FoxP3 expression reduces the number of Treg cells and is indicative of the suppression of immune tolerance to the cancer antigens in the patient.
2 . The method of claim 1 wherein the Treg cells are CD4+CD25+FoxP3+.
3 . The method of claim 1 wherein the Treg cells are reduced by decreasing the conversion of naïve T cells (CD4CD25−FoxP3') to iTreg cells.
4 . The method of claim 1 wherein the suppression of immune tolerance is by inhibition of nTreg cells.
5 . The method of claim 1 further comprising administering additional therapeutic composition, wherein the FoxP3 expression is further suppressed.
6 . The method of claim 1 wherein the composition is administered intradermally.
7 . A method for stimulating a therapeutic immune effect against cancer in a patient comprising:
suppressing the expression of FoxP3 in a patient by administering a therapeutic composition comprising allogeneic activated effector/memory Th1 cells and chaperone rich cell lysate of the cancer antigens to the patient, wherein the cells are activated by cross-linking of the CD3 and CD28 surface molecules; and
monitoring the FoxP3 expression to ensure the patient maintains suppression of immune tolerance, wherein a decrease of the FoxP3 expression reduces the number to Treg cells and induces a therapeutic effect against the cancer in the patient.
8 . The method of claim 7 wherein the Treg cells are CD4+CD25+FoxP3+.
9 . The method of claim 7 wherein the number of Treg cells are reduced by decreasing the conversion of naïve T cells (CD4CD25−FoxP3−) to iTreg cells.
10 . The method of claim 7 wherein the suppression of immune tolerance is by inhibition of nTreg cells.
11 . The method of claim 7 wherein the therapeutic effect comprises promoting anti-tumor function of effector T cells and suppressing immune tolerance of the cancer antigens.
12 . The method of claim 7 further comprising administering additional therapeutic composition, wherein the FoxP3 expression is further suppressed.
13 . The method of claim 7 wherein the composition is administered intradermally.
14 . A method of suppressing immune tolerance and promoting a therapeutic effect in patients with cancer comprising suppressing the expression of FoxP3 in patients by administering a therapeutic composition comprising allogeneic activated effector/memory Th1 cells and a chaperone rich cell lysate of cancer antigens wherein the Th1 cells and the chaperone rich cell lysate are administered at the same location, wherein the cells are activated by cross-linking of the CD3 and CD28 surface molecules; and
measuring the FoxP3 expression in the patient to ensure the patient maintains suppression of immune tolerance.
15 . The method of claim 14 wherein the Th1 cells and the cancer antigens are administered by intradermal injections.
16 . The method of claim 14 wherein the activated Th1 cells are administered prior to the cancer antigens.
17 . The method of claim 14 wherein the Th1 cells and the cancer antigens are administered at least 3 times and at intervals of about 3-10 days until the patient exhibits a therapeutic effect.